Search Results

You are looking at 101 - 110 of 203 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Yue Chen, Zi-Qi Zheng, Fo-Ping Chen, Jian-Ye Yan, Xiao-Dan Huang, Feng Li, Ying Sun, and Guan-Qun Zhou

free cervical flaps for repair. The extent of lymph node dissection was at the surgeon's discretion, mainly based on the patients’ medical histories, clinical palpation, imaging data, and intraoperative exploration. If there were several clinically

Full access

Jeffrey S. Montgomery, David C. Miller, and Alon Z. Weizer

as long as the patient has no contraindications to this treatment. Lymphadenectomy The extent of lymph node dissection needed during radical cystectomy for MIBC is controversial. 8 Data show that a more extensive lymph node dissection may

Full access

John P. Sherbeck, Lili Zhao, and Richard W. Lieberman

. Int J Gynecol Cancer 2015 ; 25 : 1437 – 1444 . 5. Alagkiozidis I Weedon J Grossman A . Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous and endometrioid adenocarcinoma: a

Full access

Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter

predictor of survival and determines the indication for additional surgery (ie, complete lymph node dissection), systemic adjuvant therapy, surveillance imaging, and frequency of clinical follow-up. However, controversy remains regarding the most appropriate

Full access

Ronald C. Chen, William U. Shipley, Jason A. Efstathiou, and Anthony L. Zietman

extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study . J Urol 2011 ; 186 : 1261 – 1268 . 23. Gray PJ Fedewa SA Shipley WU . Clinical-pathologic stage

Full access

Vishwajith Sridharan, Vinayak Muralidhar, Danielle N. Margalit, Roy B. Tishler, James A. DeCaprio, Manisha Thakuria, Guilherme Rabinowits, and Jonathan D. Schoenfeld

node dissection was associated with improved survival on univariate analysis (HR, 0.8; 95% CI, 0.68–0.94; P =.005), but this parameter was not significant on multivariate analysis. Interestingly, even when examining the more modern subgroup of patients

Full access

Lucy X. Ma, Elan D. Panov, Michael J. Allen, Gail E. Darling, Jonathan C. Yeung, Carol J. Swallow, Savtaj S. Brar, Rebecca K. Wong, Patrick Veit-Haibach, Sangeetha N. Kalimuthu, Eric X. Chen, Raymond W. Jang, and Elena Elimova

sought to elucidate the role of CRT in 458 patients who underwent curative resection with D2 lymph node dissection. 21 Following surgery, patients were randomized to receive chemotherapy alone (6 cycles of capecitabine + cisplatin [XP]) or chemotherapy

Full access

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Robin M. Lally, Terry S. Langbaum, Allison L. McDonough, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

cancers, the incidence of lymphedema 2 years after surgery was 37%. 66 In one study of 431 survivors of melanoma who had been treated with complete lymph node dissection and/or wide local excision and axillary or inguinal sentinel lymph node surgery, the

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes

base decisions regarding adjuvant treatment for select patients who do not have medical or technical contraindications to lymph node dissection (see “Lymphadenectomy Controversy,” next column, and “Sentinel Lymph Node Mapping” in the complete version of

Full access

Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

retrospective studies have suggested that it is beneficial. 57 – 59 Two randomized clinical trials from Europe reported that routine lymph node dissection did not improve the outcome of endometrial cancer patients, but lymphadenectomy did identify those with